The French National Agency for the Safety of Medicines and Health Products (ANSM) has officially authorized the start of the phase II clinical trial for assessing the non-inferiority of the PHOS-ISTOS device compared to the classical photodynamic therapy (PDT) for the treatment of actinic keratoses (record number 2016-A00010-51).
This study will be performed in the dermatology department of the Lille University Hospital (CHRU) under the responsibility of Pr. Mortier in France, and in Germany at Klinikum Vest under the responsibility of Pr. Szeimies.
